<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313596</url>
  </required_header>
  <id_info>
    <org_study_id>LT-03</org_study_id>
    <nct_id>NCT03313596</nct_id>
  </id_info>
  <brief_title>Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC</brief_title>
  <official_title>Multicenter Randomized Controlled Trial of Adenovirus-mediated Adjuvant Gene Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in
      advanced primary hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival, PFS</measure>
    <time_frame>2-year</time_frame>
    <description>PFS was measured from the day of liver transplantation to objective recurrence (MRI or CT) or HCC-related death, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, OS</measure>
    <time_frame>1-year</time_frame>
    <description>OS was measured from the day of liver transplantation to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, OS</measure>
    <time_frame>2-year</time_frame>
    <description>OS was measured from the day of liver transplantation to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the tumor progression,TTP</measure>
    <time_frame>2-year</time_frame>
    <description>TTP was the median period from the day of liver transplantation to objective recurrence (MRI or CT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival time</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>LT-only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received orthotopic LT and subsequent immunosuppression therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LT+ADV-TK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADV-Tk</intervention_name>
    <description>The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.</description>
    <arm_group_label>LT+ADV-TK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LT</intervention_name>
    <description>Orthotopic LT and subsequent immunosuppression therapy</description>
    <arm_group_label>LT-only</arm_group_label>
    <arm_group_label>LT+ADV-TK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 65 years of age (Male and Female).

          -  Clinical diagnosis of advanced primary hepatocellular carcinoma who could accept liver
             transplantation.

          -  Patients who had unresectable HCC with single tumor diameter &gt; 5 cm and ≤ 10cm; or
             numbers of multiple tumors &gt;3 and ≤ 5, and the total length of foci diameter ≤ 15 cm.

          -  Serum AFP ≤ 10000 ng/ml before liver transplantation.

          -  Child-pugh A-B.

          -  No metastasis in extrahepatic main vescular and extrahepatic lymph node detected
             during the operation and no metastasis of other organs.

          -  Provide written informed consent before screening.

        Exclusion Criteria:

          -  Metastasis in extrahepatic organs.

          -  HCC with Invasion in extrahepatic main vescular and extrahepatic organs.

          -  Contraindications of operation of other organ system.

          -  Hypersensitivity to adenovirus, GCV or similar drugs.

          -  Serious obstacle of the mechanism of coagulation, hemorrhagic tendency, and abnormal
             coagulation (≥50%).

          -  Plan to accept clinical trials of other antitumor drugs.

          -  Immunological deficit.

          -  HBsAg(+) and HBcAb(+) donor.

          -  Unsuitable participate assessed by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danhui Weng, Dr.</last_name>
    <phone>027-83663351</phone>
    <email>weng.dh@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Youan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>301 Military Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiahong Dong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chinese People's Armed Police</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunjin Zang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third XiangYa Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifa Ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lvnan Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guihua Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shusen Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongfeng Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Center Hospital of Tianjin</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongyang Shen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Wen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

